$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000162828021010200 Filed on May 14, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$0.00	$6.000K
YoY Change	-100.0%	-99.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.480M	$2.420M
YoY Change	2.48%	-31.44%
% of Gross Profit
Research & Development	$3.320M	$3.119M
YoY Change	6.44%	-47.87%
% of Gross Profit
Depreciation & Amortization	$335.0K	$126.0K
YoY Change	165.87%	-74.9%
% of Gross Profit
Operating Expenses	$5.798M	$5.541M
YoY Change	4.64%	-41.77%
Operating Profit	-$5.798M	-$5.535M
YoY Change	4.75%	102.15%
Interest Expense	$216.0K	$489.0K
YoY Change	-55.83%	-15.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.013M	-$5.945M
YoY Change	1.14%	82.36%
Income Tax	$0.00	-$8.000K
% Of Pretax Income
Net Earnings	-$6.013M	-$5.937M
YoY Change	1.28%	82.12%
Net Earnings / Revenue		-98950.0%
Basic Earnings Per Share	-$0.08
Diluted Earnings Per Share	-$0.08	-$246.9K
COMMON SHARES
Basic Shares Outstanding	71.29M shares	21.04M shares
Diluted Shares Outstanding	71.29M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.60M	$28.10M
YoY Change	12.46%	172.82%
Cash & Equivalents	$31.60M	$28.05M
Short-Term Investments
Other Short-Term Assets	$1.492M	$955.0K
YoY Change	56.23%	19.23%
Inventory
Prepaid Expenses	$3.314M	$3.924M
Receivables	$100.0K	$700.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$36.54M	$33.61M
YoY Change	8.72%	89.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$219.0K	$801.0K
YoY Change	-72.66%	-49.87%
Goodwill
YoY Change
Intangibles	$116.0K	$159.0K
YoY Change	-27.04%	-60.93%
Long-Term Investments
YoY Change
Other Assets	$0.00	$439.0K
YoY Change	-100.0%	230.08%
Total Long-Term Assets	$3.304M	$1.399M
YoY Change	136.17%	-34.57%
TOTAL ASSETS
Total Short-Term Assets	$36.54M	$33.61M
Total Long-Term Assets	$3.304M	$1.399M
Total Assets	$39.84M	$35.01M
YoY Change	13.81%	76.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$810.0K	$1.030M
YoY Change	-21.36%	-61.13%
Accrued Expenses	$620.0K	$860.0K
YoY Change	-27.91%	-50.72%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.700M	$14.60M
YoY Change	-67.81%	-5.81%
Total Short-Term Liabilities	$9.864M	$19.79M
YoY Change	-50.15%	-20.35%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$2.900M	$318.0K
YoY Change	811.95%	-71.25%
Total Long-Term Liabilities	$2.900M	$318.0K
YoY Change	811.95%	-71.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.864M	$19.79M
Total Long-Term Liabilities	$2.900M	$318.0K
Total Liabilities	$12.73M	$20.10M
YoY Change	-36.68%	-22.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$433.1M	-$417.3M
YoY Change	3.79%	5.37%
Common Stock	$460.2M	$432.2M
YoY Change	6.48%	10.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.11M	$14.90M
YoY Change
Total Liabilities & Shareholders Equity	$39.84M	$35.01M
YoY Change	13.81%	76.11%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$6.013M	-$5.937M
YoY Change	1.28%	82.12%
Depreciation, Depletion And Amortization	$335.0K	$126.0K
YoY Change	165.87%	-74.9%
Cash From Operating Activities	-$5.711M	-$6.002M
YoY Change	-4.85%	35.39%
INVESTING ACTIVITIES
Capital Expenditures	$53.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$53.00K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.382M	$1.000K
YoY Change	638100.0%	-99.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.336M	-$67.00K
YoY Change	-9556.72%	-110.2%
NET CHANGE
Cash From Operating Activities	-$5.711M	-$6.002M
Cash From Investing Activities	-$53.00K	$0.00
Cash From Financing Activities	$6.336M	-$67.00K
Net Change In Cash	$572.0K	-$6.069M
YoY Change	-109.42%	67.88%
FREE CASH FLOW
Cash From Operating Activities	-$5.711M	-$6.002M
Capital Expenditures	$53.00K	$0.00
Free Cash Flow	-$5.764M	-$6.002M
YoY Change	-3.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:RevenueUnderCollaborationsMember
CY2021Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:RevenueUnderCollaborationsMember
CY2018Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0833
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-35670
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4224 Campus Point Court, Suite 210
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	City Area Code CityAreaCode	858
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	202-6300
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	RGLS
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	74923660	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31597000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31087000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	72000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	503000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3314000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3314000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	620000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581000	USD
CY2021Q1	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	726000	USD
CY2020Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1097000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	802000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1743000	USD
CY2021Q1	us-gaap	Debt Current DebtCurrent	4657000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	4652000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2249000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2970000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9864000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11578000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2866000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1338417	shares
CY2021Q1	us-gaap	Other Assets Current OtherAssetsCurrent	1492000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1826000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	36537000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	36730000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	219000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	116000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	125000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2969000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000	USD
CY2021Q1	us-gaap	Assets Assets	39841000	USD
CY2020Q4	us-gaap	Assets Assets	37604000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	810000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	535000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	12730000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	11578000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1338417	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74689132	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74689132	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67432712	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67432712	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	75000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	460092000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	453002000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433058000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427045000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	27111000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	39841000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37604000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3320000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3119000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2478000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2422000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	5798000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	5541000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5798000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5535000	USD
CY2021Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	1000	USD
CY2020Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	79000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	216000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	489000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6013000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5945000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-8000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6013000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	71290918	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24064373	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	26000	USD
CY2021Q1	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	666000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5713000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	691000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6013000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	27111000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	823000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	14902000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6013000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	335000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	126000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	691000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	823000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	10000	USD
CY2020Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	105000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-432000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-466000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-356000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-264000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	275000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-291000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	14000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-182000	USD
CY2021Q1	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-371000	USD
CY2020Q1	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	125000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-941000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1144000	USD
CY2021Q1	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	90000	USD
CY2020Q1	rgls	Operating Lease Right Of Use And Lease Liabilities Net Gain Loss OperatingLeaseRightOfUseAndLeaseLiabilitiesNetGainLoss	-36000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-589000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-315000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5711000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6002000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6382000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	26000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021Q1	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	72000	USD
CY2020Q1	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	68000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6336000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-67000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	572000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6069000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31659000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28052000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31597000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28052000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	62000	USD
CY2020Q1	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31659000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28052000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	109000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	384000	USD
CY2021Q1	rgls	Noncash Acquisition Of Property And Equipment NoncashAcquisitionOfPropertyAndEquipment	24000	USD
CY2020Q1	rgls	Noncash Acquisition Of Property And Equipment NoncashAcquisitionOfPropertyAndEquipment	0	USD
CY2021Q1	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	490500000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31600000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesOur condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27741065	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	36680830	shares
CY2020Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2021Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	24902000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	26901000	USD
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	700000	USD
CY2020Q2	rgls	Forgiveness Amount Threshold ForgivenessAmountThreshold	500000	USD
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74689132	shares
CY2021Q1	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2021Q1	rgls	Sale Of Stock Value Of Shares Available SaleOfStockValueOfSharesAvailable	28900000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9186000	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	91967000	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	691000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	823000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	359000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	754000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	776000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	800000	USD
CY2021Q1	rgls	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	1101000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3790000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	567000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3223000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	357000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2866000	USD

Files In Submission

Name	View Source	Status
0001628280-21-010200-index-headers.html	Edgar Link	pending
0001628280-21-010200-index.html	Edgar Link	pending
0001628280-21-010200.txt	Edgar Link	pending
0001628280-21-010200-xbrl.zip	Edgar Link	pending
ex-311x20210331.htm	Edgar Link	pending
ex-312x20210331.htm	Edgar Link	pending
ex-321x20210331.htm	Edgar Link	pending
exhibit103-sdx758866xv2xre.htm	Edgar Link	pending
exhibit104-sdx754314xv2xre.htm	Edgar Link	pending
exhibit105-sdx753896xv4x.htm	Edgar Link	pending
exhibit105-sdx753896xv4x001.jpg	Edgar Link	pending
exhibit105-sdx753896xv4x002.jpg	Edgar Link	pending
exhibit105-sdx753896xv4x003.jpg	Edgar Link	pending
exhibit105-sdx753896xv4x004.jpg	Edgar Link	pending
exhibit105-sdx753896xv4x005.jpg	Edgar Link	pending
exhibit105-sdx753896xv4x006.jpg	Edgar Link	pending
exhibit106-amendmentnumber.htm	Edgar Link	pending
exhibit107-haganbasesalary.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20210331.htm	Edgar Link	pending
rgls-20210331.xsd	Edgar Link	pending
rgls-20210331_cal.xml	Edgar Link	unprocessable
rgls-20210331_def.xml	Edgar Link	unprocessable
rgls-20210331_htm.xml	Edgar Link	completed
rgls-20210331_lab.xml	Edgar Link	unprocessable
rgls-20210331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2021 Q1 Form 10-Q Financial Statement

#000162828021010200 Filed on May 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2021 Q1 Form 10-Q Financial Statement

#000162828021010200 Filed on May 14, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls